BACKGROUND: Hepatitis C virus (HCV) infection is widespread and associated with high economic costs and reduced quality of life, but the impact of untreated HCV infection on patient outcome is not well understood. AIMS: To estimate the impact of untreated HCV infection on work productivity, daily activity, healthcare use, economic costs, and health-related quality of life (HRQoL). METHODS: Respondents to the 2010 US National Health and Wellness Survey (n = 75,000) reporting physician diagnosis of HCV infection but not current or previous treatment (patients) were matched to respondents without HCV infection (controls) by use of propensity scores. Those reporting infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were excluded. Self-reported work impairment, activity impairment, healthcare resource use, and HRQoL were compared between patients and controls. Indirect and direct costs were estimated. RESULTS: A total of 306 patients met inclusion criteria. Patients were more impaired at work than controls, with overall work impairment of 26 % versus 15 %, respectively (P < 0.001), mostly because of presenteeism in both groups. Annual productivity losses were estimated at $10,316 per employed patient compared with $5,469 per control (P < 0.001). Patients used more healthcare, with all-cause healthcare costs estimated at $22,818 per patient annually, compared with $15,362 per control (P < 0.001). HRQoL and activity impairment were also worse among patients than controls. CONCLUSIONS: Untreated HCV infection is associated with substantial economic costs to society, through loss of productivity and increased use of healthcare resources, and with impaired well-being of the patient.
BACKGROUND:Hepatitis C virus (HCV) infection is widespread and associated with high economic costs and reduced quality of life, but the impact of untreated HCV infection on patient outcome is not well understood. AIMS: To estimate the impact of untreated HCV infection on work productivity, daily activity, healthcare use, economic costs, and health-related quality of life (HRQoL). METHODS: Respondents to the 2010 US National Health and Wellness Survey (n = 75,000) reporting physician diagnosis of HCV infection but not current or previous treatment (patients) were matched to respondents without HCV infection (controls) by use of propensity scores. Those reporting infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) were excluded. Self-reported work impairment, activity impairment, healthcare resource use, and HRQoL were compared between patients and controls. Indirect and direct costs were estimated. RESULTS: A total of 306 patients met inclusion criteria. Patients were more impaired at work than controls, with overall work impairment of 26 % versus 15 %, respectively (P < 0.001), mostly because of presenteeism in both groups. Annual productivity losses were estimated at $10,316 per employed patient compared with $5,469 per control (P < 0.001). Patients used more healthcare, with all-cause healthcare costs estimated at $22,818 per patient annually, compared with $15,362 per control (P < 0.001). HRQoL and activity impairment were also worse among patients than controls. CONCLUSIONS: Untreated HCV infection is associated with substantial economic costs to society, through loss of productivity and increased use of healthcare resources, and with impaired well-being of the patient.
Authors: Herbert L Bonkovsky; Kristin K Snow; Peter F Malet; Carla Back-Madruga; Robert J Fontana; Richard K Sterling; Clark C Kulig; Adrian M Di Bisceglie; Timothy R Morgan; Jules L Dienstag; Marc G Ghany; David R Gretch Journal: J Hepatol Date: 2006-11-27 Impact factor: 25.083
Authors: John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir Journal: N Engl J Med Date: 2009-04-30 Impact factor: 91.245
Authors: Chia C Wang; Elizabeth Krantz; Jared Klarquist; Meighan Krows; Lanamarie McBride; Edward P Scott; Thomas Shaw-Stiffel; Scott J Weston; Hanne Thiede; Anna Wald; Hugo R Rosen Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: T Joseph Mattingly; Julia F Slejko; Eleanor M Perfetto; Shyamasundaran Kottilil; C Daniel Mullins Journal: Patient Date: 2019-12 Impact factor: 3.883
Authors: Farnaz Vahidnia; Susan L Stramer; Debra Kessler; Beth Shaz; German Leparc; David E Krysztof; Simone A Glynn; Brian Custer Journal: Qual Life Res Date: 2016-08-17 Impact factor: 4.147
Authors: Shannon Allen Ferrante; Jagpreet Chhatwal; Clifford A Brass; Antoine C El Khoury; Fred Poordad; Jean-Pierre Bronowicki; Elamin H Elbasha Journal: BMC Infect Dis Date: 2013-04-27 Impact factor: 3.090
Authors: Patricia A M Kracht; Faydra I Lieveld; Linde M Amelung; Carina J R Verstraete; Eveline P Mauser-Bunschoten; Joep de Bruijne; Peter D Siersema; Andy I M Hoepelman; Joop E Arends; Karel J van Erpecum Journal: Infect Dis Ther Date: 2018-08-03
Authors: T Joseph Mattingly; Julia F Slejko; Eberechukwu Onukwugha; Eleanor M Perfetto; Shyamasundaran Kottilil; C Daniel Mullins Journal: Pharmacoeconomics Date: 2020-02 Impact factor: 4.981